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ABSTRACT 
There is currently a heightened interest in the use of plants from pharmaceutical industries due to 
its genetic diversity and ability to make specialized compounds as a defense mechanism. More 
specifically, the National Cancer Institute previously performed a high throughput screening to 
identify over 88,000 extracts with anticancer properties. However, the use of whole plants to 
generate these specialized metabolites has numerous drawbacks, specifically the low and 
inconsistent production of compounds. This project aims to improve upon this screening system 
and develop a high-throughput screening system with the use of plant cell extracts to produce more 
reliable and consistent results, which can potentially lead to the discovery of novel specialized 
metabolites. By determining the optimal concentration of the solvent in which to extract plant 
metabolites as 0.01% (v/v) ethanol, the effects of the compounds being tested are further validated 
as it ensures there is very little interference or influence from the solvent. Additionally, the 
application of pure paclitaxel allowed the development of a standard response from each cancer 
cell line. Furthermore, the use of Taxus extracts on the screening system validated its use as the 
paclitaxel present in the extracts, specifically in 48-82A-2 and 1101-62A-5, resulted in consistent 
results in three different cancer cell lines as a decrease in cell viability.  
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CHAPTER 1. INTRODUCTION 
Plants have been historically utilized for medicinal purposes, and therefore, there is a significant 
research focus for drug discovery. In 1971, extracts obtained from the bark of Taxus brevifolia 
were found to have cytotoxic properties against various types of cancer cells, which led to the 
development of the first FDA-approved plant cell culture-based chemotherapy drug, TaxolTM 
(generic name paclitaxel)1. This project ultimately aims to search for other plant extracts (and 
compounds) that exhibit anticancer properties to potentially become new chemotherapy drug 
candidates.  
1.1 Plants, the Environment, and their Pharmaceutical Promise 
1.1.1 Specialized Metabolism 
Historically, over 80% of the world has relied on plants for traditional medicine2. This can be 
attributed to the bioactive specialized (formerly known as secondary) metabolites that plants 
produce and secrete to defend or adapt to their environment. Fortunately, many of these 
compounds have been found to demonstrate therapeutic properties. Plants produce two broad 
classes of metabolites: conserved and specialized metabolites. Conserved metabolites are 
classified as compounds produced to sustain plant life and growth, such as cell division, 
photosynthesis, storage, and reproduction3. Specialized metabolites, on the other hand, are very 
low in abundance, and stored away in specific organelles of the cell3. Specialized metabolites play 
a significant role in a plant’s adaptation to the environment as they are specific compounds that 
allow the plant to better integrate within the ecosystem3 (Bourgaud, 2001). For instance, to combat 
stressful situations in the environment, phytoalexins are secreted to protect against pathogens or 
alleopathy to protect from other plants4. Additionally, UV absorbing compounds can be secreted 
to protect the leaves from radiation4. Overall, different classes of specialized metabolites harnessed 
from medicinal plants provide a valuable platform for drug development in the pharmaceutical 
industry.   
1.1.2 Impact in the Pharmaceutical Industry 
For decades, the mission of the pharmaceutical industry has been to “discover and develop new 
drugs for the treatment of disease”5. This mission still holds true today as drug development 
continually evolves to meet consumers’ needs and demands. Drug development primarily relied 
on metabolites produced by microorganisms5. However, from 1930 to 1970, pharmaceutical 
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companies, such as Merck and Bristol-Meyers Squibb, focused on their efforts on manufacturing 
natural products from plants. Pharmaceutical manufacturers have taken a liking to plant and other 
natural products because of their genetic diversity and ability to make unique compounds. During 
1990 to 2000, or more commonly known as the Green Rush, pharmaceutical companies worldwide 
increased their research efforts to discover novel natural products6. With technologies such as the 
High-Performance Liquid Chromatography (HPLC), High Resolution Mass Spectrometry 
(HRMS), and High Field Nuclear Magnetic Resonance Spectrometry (NMR), it was made possible 
to characterize these natural products. Although natural products were highly beneficial, 
harvesting the plants posed many problems. For instance, there are high harvesting costs as many 
plant species flourish in specific environments and depletion of species lead to endangerment7 
(citation). Despite these setbacks, plants have continuously contributed to the discovery and 
development natural product-based medicine. 
1.1.3 Impact in Research  
Plants have gained momentum in cancer research as at least 250,000 plant species have been 
reported to contain significant anticancer properties8. This finding led to the creation of the 
Developmental Therapeutics Program (DTP) by the National Cancer Institute (NCI) in 1955 in 
order to discover and develop anticancer agents as potential therapeutic treatments for cancer 
patients8. Since its creation, the DTP has screened over 88,000 different plant extracts against 60 
human tumor cell lines, including lung, brain, colon, ovarian, and breast cancer8. This high-
throughput screening from the DTP sparked multiple screenings of different plant extracts on 
tumor cell lines done at various institutions. The anti-proliferative properties of grape extracts were 
assessed against liver (HepG2) and cervical (HeLa) cancer cell growth, as grapes have been known 
for their positive effects on human health9. Plant extracts can exhibit more than one biological 
activity. Lemon balm, or Melissa officinalis, is commonly used for sleep and gastrointestinal 
disorders; however, more recently it was found to inhibit the viability of various tumor cell lines, 
such as human colon cancer (HCT 116) and breast cancer (MCF-7), in a concentration-dependent 
manner10. These findings show promise in the use of plant extracts as chemotherapy drugs.   
1.1.4 Paclitaxel 
Paclitaxel (TaxolTM) was discovered in the 1960’s from the extensive screening performed the 
NCI. Taxanes are a family of molecules that all exhibit a similar molecular structure and some 
serve as microtubule inhibitors. As a member of the taxane class, the primary mechanism of 
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paclitaxel is the “suppression of microtubule spindle dynamics”11. This inability to transition from 
metaphase to anaphase leads to the inhibition of mitosis, which ultimately causes the cell to 
undergo apoptosis. The unique characteristic of paclitaxel that makes it very successful as a 
chemotherapy drug is its ability to stabilize microtubules to prevent tubulin disassembly, especially 
against rapidly dividing cells such as those creating tumors12.   
 
Originally extracted from the Pacific yew tree, or Taxus breviforia, paclitaxel showed unique anti-
proliferative properties that propelled it to become the first FDA approved plant cell culture-based 
chemotherapy drug11. As a natural product therapy, it gained tremendous success due to its high 
response rates against a variety of tumors, such as breast, ovarian, lung, and bladder cancer.  
1.2 Plant Cell Culture 
Plant tissue culture has played a more crucial role in the production of small molecules and 
recombinant pharmaceuticals13 (Xu, 2015). Plant cell culture is a technique where de-differentiated 
cells, tissues, and organs of plants are introduced into a sterile artificial environment with 
appropriate conditions for the plant cells to thrive13. Because plant cell culture is an in vitro 
technique, conditions can be changed to optimize synthesis and yields of specialized metabolites14. 
Cell growth is mainly supported by a basic medium, composed of water, macro- and micro-
nutrients, and a carbohydrate source, to replace the carbon obtained through the atmosphere by 
photosynthesis7.  The cells usually form a callus – an undifferentiated mass of cells which can give 
rise to a functional part of a plant due to its totipotency – capable of growing, dividing, and giving 
rise to any cell type15. Suspension cultures arises when the callus cells are allowed to proliferate 
in a liquid medium in order to break up the cell aggregate of the callus for faster proliferation. 
Figure 1 demonstrates the development of a plant cell culture.  
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Figure 1. Development of a plant tissue culture. A) sterile plant; B) callus culture; C) 
suspension culture. (Recent advances towards development and commercialization of plant cell 
cultures processes for the synthesis of biomolecules. (Adapted from Wilson, 2012)  
1.2.1 Using Whole Plants for Drug Discovery 
One of the main gaps in the medicinal assessments of plants is the inconsistent production of 
specialized metabolites and loss of original plant collections1. Some plants have relatively short 
lifespans, therefore, it is possible that once the specialized metabolites have been characterized, 
the primary plant source has been depleted. The metabolite may only be produced by a specific 
species or genus, and may only be activated during a specific developmental stage or under a 
particular environmental condition16. The entire plant may be unable to produce the specialized 
metabolite, only a specific section, or a different compound profile may be present. Different 
samples of the sample plant can contain various amounts of metabolic compounds, as the 
metabolites are produced and stored in different plant organs and/or cells6. Furthermore, 
harnessing these specialized metabolites from whole plants can be very challenging and expensive, 
may miss identification of potent compounds, and may only be able to collect and produce very 
low yields16.These challenges of using whole plants for drug discovery can be overcome by 
assessing cells as plant cell culture, a generic cell that can be accounted for the whole plant under 
different conditions.  
1.2.2 Benefits of Plant Cell Cultures 
Plants cells grown in vitro, however, have a more controlled, sterile environment that allows for 
precise and consistent control over cell growth and protein production13 (Xu, 2015). With plant 
cell cultures, the continuous production of specialized metabolites in large-scale bioreactors can 
be used to scale up the production of the plant cell cultures16,17. Plant cell cultures are less prone 
to the possibility of contamination with agrochemicals and fertilizers, pests and diseases, different 
cultivation conditions, such as soil quality, microclimate, and other local differences7. 
Furthermore, plant cell culture allows for the conservation of endangered plant species for future 
generations16. These benefits of plant cell cultures therefore make them more advantageous 
compared to whole plants.  
1.2.1 UMASS Plant Cell Culture Library 
The University of Massachusetts–Amherst contains one of the largest living plant cell culture 
collections, from over 1,000 diverse plant species worldwide18. This library is accessible for the 
discovery and identification of novel specialized metabolites that can potentially be harnessed for 
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medicinal purposes18. Additionally, the plant cell culture library (PCCL) contains a database of 
medicinal properties from peer-reviewed literature based on the cultures in the collection, such as 
antivirial, antifungal, and anticancer. Through the PCCL, it is possible to re-create and improve 
upon the screening performed by the NCI. This provides the opportunity to use of plant cell 
cultures rather than whole plants for controlled specialized metabolite synthesis (e.g., under stress 
conditions).   
1.3 Elicitation 
As previously mentioned, plants have the ability to produced specialized metabolites in response 
to pathogenic attacks, such as from bacteria and fungi. As plant cell cultures are utilized, elicitation 
arises as a promising method to stimulate and enhance the production of specialized metabolites 
in plant cells in vitro4. Elicitation is defined as the stimulation of stress conditions that occur in the 
natural environment19. Elicitors can be classified into two broad categories: abiotic and biotic 
elicitors (Figure 2).  
 
Figure 2. Classifications of elicitors. (Adapted from Naik & Al-Khayri, 2015) 
 
1.3.1 Abiotic Elicitors 
Abiotic elicitors can be classified as physical factors and chemical compounds that increase flux 
to the production of specialized metabolites19. Examples of inorganic elicitors are salts and heavy 
metal ions (e.g., copper, cadmium, and calcium)4. Physical stressors can be considered as UV light, 
windfall, freezing and thawing cycles, high pH, or high pressure4,16. Additionally, chemical 
stressors such as pesticides and aerosols can disrupt the plant cell membranes and elicit specialized 
metabolite synthesis19. 
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1.3.2 Biotic Elicitors 
Biotic elicitors can be classified as any compound of biological origin such as yeast, pathogens, 
and bacteria16,20. Pathogens trigger a defense response by inducing a signal cascade in the plant 
leading to alterations in gene expression. Yeast is a biotic elicitor that can be used in many 
applications. For example, it was used to elicit the production of ethylene in a tomato19. In addition, 
other fungi can be used to elicit specialized metabolites in medicinal plant cell cultures. Fungal 
spores have been shown to increase the amount of codeine and morphine in the plant species 
Papaver somniferum19. Taxus chinensis cells have also been treated with an endophytic fungus 
that increased cellular production of paclitaxel. Scientists believe that biotic elicitors function by 
binding to the membrane receptor of the plant that signals reactive oxygen species (ROS) to be 
produced which are converted into specialized metabolites19.   
1.3.2.1 Methyl Jasmonate 
Jasmonates, more specifically methyl jasmonate (MeJa), are classified as biotic elicitors as they 
are commonly secreted by plants when attacked or wounded to signal stress to other cells in the 
organism16. MeJa plays a significant role in the regulation of plant defense genes through signal 
transduction pathways leading to the production of specialized defense compounds. Because of 
this property, the application of MeJa to plant cell cultures can induce production of various 
specialized metabolites, such as terpenoids, flavonoids, and alkaloids4. In regards to the production 
of paclitaxel, MeJa was reported to be one of the most effective methods in enhancing paclitaxel 
production from Taxus cell cultures16. MeJa has been found broadly to influence most plant 
species; for example, it was beneficial for vinblastine, an anticancer compound extracted from 
Catharantus roseus hair roots. With an optimal concentration of MeJa, it is possible to enhance 
production of a variety of specialized metabolites, many with anticancer properties.  
1.3.2.2 Endophytic Fungi and Yeast Extracts 
As previously mentioned, elicitation plays a key role in plant production of specialized 
metabolites, which can be utilized for pharmaceutical purposes. Though the yield of specialized 
metabolites within plant cell cultures is often low in comparison to that of whole plants, there is a 
wide range of bioactive compounds detected within the plant cell cultures4. The use of fungal cell 
wall fragments of Trichoderma viride, Aspergillus niger, and Fusarium moniliforme was used to 
elicit Catharanthus roseus cell cultures to enhance the levels of specialized metabolites, such as 
ajmalicine. In these studies, higher concentration of the fungal fragments increased the production 
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levels of ajmalicine4. Biotic elicitors, such as endophytic microbes and yeast, show significant 
promise for increasing the yield of specialized metabolites in plants as they have been shown to 
have coevolved with similar pathways to produce natural products21. 
 
Endophytic fungi are of particular interest as they have demonstrated an established relationship 
with the plant host through parasitic or mutualistic methods without causing negative effects to the 
plant22. The synergistic relationship between endophytic fungi and plants suggest endophytes as a 
promising source of elicitors of specialized metabolites as it is utilized for the facilitation of the 
fungi’s innate connection to the plant and the protection from invading pathogens23. Because of 
this synergistic relationship, both endophytic fungi and their respective plant host share similar 
metabolic pathways that allow the transfer of information and production of similar specialized 
metabolites22. Plants with medicinal properties are often hosts to endophytic fungi which provides 
the additional production of novel and pharmaceutically promising metabolites22. For instance, a 
study performed by Wu, et. al. (2015) demonstrated how endophyte-derived secondary metabolites 
can play a role in the anticancer properties of fruit. Based on their study, they determined three of 
the leaf-derived endophytic fungi inhibited the growth of lung, prostate, and breast, all of which 
are human carcinoma cell lines22.  
To attain the elicited plant extracts for this project, Saccharomyces cerevisiae (common baker’s 
yeast), a thoroughly researched fungus, was used as the fungal elicitor. Because yeast, fungi, and 
mammals share the same highly conserved basic signaling pathways and cellular machinery, S. 
cerevisiae is an excellent model for the identification of anticancer and antifungal compounds24. 
Qaddouri reported to identify “14 plant extracts and 8 natural product molecules with clear growth-
inhibitory effects” with S. cerevisiae (2011). This study focused on the effects of a plant-derived 
natural alkaloid product, Lyc, on yeast growth and it was found that Lyc heavily inhibited the 
growth of yeast25. This finding using S. cerevisiae suggests yeast extract as a promising model for 
the identification of natural products with anti-proliferative properties and potential therapeutic 
value25.  
 
Drug discovery has been hindered due to the similarities between the targeted fungal cell and the 
infected mammalian cell as they share similar structural and functional cellular properties25. The 
use of S. cerevisae as a biotic elicitor may allow the discovery of plant-derived compounds with 
  8 
not only antifungal properties but also anticancer properties. Due to the evolutionary similarity 
between mammalian and fungal cells, fungal species used for drug studies have human homologs 
and share the similar drug non-selectivity26. For instance, rapamycin, a natural product with 
antimicrobial and immunosuppresant activities, is found to be toxic to numerous tumor cell lines 
and is a potent antifungal agent25. Rapamycin holds antifungal and anticancer properties as its 
production is derived from a highly conserved binding protein between yeast and mammalian cells, 
the peptide propel isomerase, FKBP1225. As S. cerevisae is a highly researched species, its 
chemical-genetic profile greatly contributes to the assessment of the mode of action by bioactive 
compounds in human cells25. 
1.4. Mammalian Cell Cultures 
Various experiments in this work utilized the following mammalian cancer cell lines, HeLa, A549, 
and HCT 116, to assess the potential medicinal properties of plant cell extracts. The properties of 
the plant extracts can be quantified using cell based assays, such as an MTT assay. The MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium) assay is a reduction 
assay. The ability of a viable cell to metabolize and covert MTT into formazan crystals by reducing 
NADH to NAD+, signified by a purple color, determines mitochondrial activity of the cell line 
which quantifies its viability (van Meerlo, NCBI) 
1.4.1.1  HeLa 
The cervical cancer cell line, HeLa, originated from a 31-year-old African American cervical 
cancer patient, Henrietta Lacks (Baker, 2011). It is hypertriploid and has a modal chromosome 
number of 82, with four copies of chromosome 12 and three copies of chromosomes 6, 8, and 17; 
therefore, it has an abnormal amount of chromosomes (ATCC). HeLa was considered to be the 
first immortal cell line to be successfully cultured in the lab, which enabled numerous scientific 
and medical breakthroughs (Lucey, 2009). Various types of plant extracts with medicinal 
properties, ranging from grape extracts to Turkish medicinal plants, have been tested against HeLa 
to assess anticancer, antiproliferative, and overall cytotoxic properties (Bozkurt-Guzel, 2017; 
Reddy, 2013). 
1.4.1.2 HCT 116 
HCT 116 is a male colon cancer cell line with a near diploid stem line chromosome and modal 
number at 45 (62%) and polyploids occurring at 6.8% (ATCC). Numerous plant extracts have 
  9 
been tested against HCT 116, such as Melissa officinalis, an herbal tea extract, and rice suspension 
cultures. With HCT 116, M. officinalis reported to have antiproliferative properties and the rice 
cultures were able to inhibit the growth of the cancer cell line without affecting the growth of the 
normal cell lines27. 
1.4.1.3 A549 
The lung cancer cell line, A549, was obtained from a 58-year-old Caucasian male lung cancer 
patient. A549 is a hypotriploid human cell line with the modal chromosome number of 66 
occurring in 24% of the cells (ATCC). A549 is a commonly used cell line against numerous plant 
extracts, such as Ebenus boissieri, to test for immunomodulatory effects, and cytotoxic and 
antiproliferative properties28.   
1.5 Method Development 
The overall aim of this project is to validate the use of a high-throughput screening system of plant 
cell lines using a model medicinal species, Taxus, as it is known to produce paclitaxel. For this 
project, we developed three objectives to enable the validation this unique screening system, which 
can allow the potential discovery of novel metabolites with anticancer compounds for drug 
development.  
1.5.1 Objective 1. Method Development: Selecting an optimal solvent to test 
extracts against cancer cell lines.  
As the first objective was to select an optimal solvent for the screening platform, our goal was to 
identify a solvent with minimal effect on cell viability of the three cancer cell lines. The solvents 
being assessed were dimethyl sulfoxide (DMSO) and ethanol. Choosing an optimal solvent is 
important as it is used to dissolve the plant cell extracts and paclitaxel.  
1.5.2 Objective 2. Method Development: Screening of Known Paclitaxel 
Concentrations. 
The second objective was to perform an initial test to verify the cytotoxic effects of paclitaxel on 
the three cancer cell lines: HeLa, A549, and HCT 116, by testing known paclitaxel concentrations. 
In order to achieve this goal, serial dilutions of paclitaxel were used to produce different 
concentrations ranging from 5 µM to 500 µM, based on values previously reported in the literature. 
From these studies, it was possible to determine the most potent paclitaxel concentration for each 
cell line.  
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1.5.3 Objective 3. Method Validation: Use of Taxus Cell Cultures. 
The final objective was to validate the effectiveness of the screening platform by using Taxus 
extracts as they are found to produce paclitaxel. Through the use of this platform, we are also able 
to assess if these Taxus extracts being tested are producing paclitaxel and validate their effects 
against the three cancer cell lines. The Taxus cell cultures obtained from the Roberts’ lab are 
known to produce paclitaxel and it is expected that when elicited with methyl jasmonate, there will 
be an enhanced production of paclitaxel, while when elicited with ethanol, there will be minimal 
or no production of paclitaxel.  
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CHAPTER 2. METHODOLOGY 
 
2.1 Maintenance of Taxus Cell Cultures 
Taxus cultures utilized for these experiments (i.e., 48-82A-2, 48-82A-3, 48-82A-4, 48-82A-32, 
1101-62A-5) originated from Taxus chinensis. Cells were cultured in suspension in aqueous 
medium containing 20 g/L sucrose, 3.21 g/L Gamborg’s B5, 8.3	×	10() M 6-benzylaminopurine 
(BA), 1.03	×	10() M 1-naphthaleneacetic acid supplemented with antioxidants which 
are		1.42	×	10()	M	ascorbic acid, 1.3	×	10() M citric acid, and 9.99	×	10() M L-glutamine. 
Cells were maintained in the dark at 25°C on an orbital shaker at 125 rpm and cultured every 14 
days. For elicitation purposes, the two 50 mL flasks of cells were elicited with either sterile 200 
µM methyl jasmonate (+MeJa) or ethanol (-MeJa) on day 7.  
2.2 Preparation of Taxus Extracts 
Elicited Taxus culture samples (1 mL total culture collected in a microfuge tube) were collected 
on day 14 and evaporated overnight for approximately 9 hours in an evaporative centrifuge. The 
plant cells were then extracted with 1 mL acidified methanol (0.01% (v/v) acetic acid) at room 
temperature with a combination of homogenization procedures. Such homogenization steps 
included periodic vortexing, sonication in an ultrasonic bath for 20 min, and manual 
homogenization using a spatula. The combined extracts were centrifuged at 20,000 rpm for 20 
minutes to remove and collect the supernatant liquid. The supernatants from each cell line under 
either +MeJa or –MeJa were then pooled together and vortexed. The combined supernatant was 
then again evaporated using an evaporative centrifuge for 90 minutes at 10,000 rpm. To avoid 
paclitaxel degradation, the Taxus extracts were stored in an -80°C freezer until they were ready to 
be used. Prior to treating the mammalian cancer cells with the Taxus extracts, the final plant extract 
was dissolved with 100% ethanol in sterile conditions.   
2.3 Cell Cultures 
HCT116 cells, A549 cells, and HeLa cells were cultured in McCoy’s, or RPMI medium, 
respectively, with 10% FBS and 1% penicillin-streptomycin (Gibco). The monolayer cultures were 
maintained in 75 cm2 tissue culture flasks at 37°C in a humidified 5% CO2 incubator. To treat the 
cells, 1 mL of ethanol was used to dissolve paclitaxel and Taxus extracts; 0.01% (v/v) ethanol and 
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compound solution were used to treat each well in a 96-well plate, amounting to 2 µL per well. A 
hemocytometer was used to quantify the number of viable cells used for the MTT experiments. 
2.4 Cytotoxicity Assay 
The cytotoxicity levels of the Taxus extracts, solvents, and paclitaxel on HeLa, A549, and HCT 
116 cell was determined using 3-(4,5-dimethylthiazol-2-yl)-2, diphenyltetrazolium bromide 
(MTT) (Thermo Fisher Scientific). For the MTT assay, 5000 tumor cells/well were seeded into 
96-well tissue culture plates. Cells were treated with 2 µL either solvent, paclitaxel, or Taxus 
extract after a 24-hour incubation period at 37°C in a humidified 5% CO2 incubator. The cells were 
given fresh RPMI medium without phenol red after 72 hours with the treatment in addition to 10 
µL MTT (5 mg/mL; Vybrant) into each well. After 4 hours of incubation, the MTT was aspirated 
off and cells were lysed with 100 µL of dimethylsulfoxide (DMSO). Metabolically viable cells 
were assessed based on their ability to metabolize and convert MTT into formazan crystals. Based 
on the absorbance recorded through Multiskan GO 96-well microtiter plate reader at 549 nm 
(ThermoFisher Scientific). The levels of cell viability were calculated using the following formula: 
% viability = [(A – B)/A] ´ 100%, where A is denoted as the average absorbance of the control 
cells and B is denoted as the absorbance from each individual treatment.  
2.5 Statistical Analysis 
Results are reported as mean ± standard deviation. The data obtained from the experiments were 
tested for statistical significance using a repeated-measures one-way ANOVA for tests 
determining the optimal concentration of a solvent and experiments testing known paclitaxel 
concentrations. A two-way ANOVA using Tukey’s test was used in tests comparing effects of 
DMSO and ethanol, and Taxus extracts between +MeJa and –MeJa. The GraphPad Prism 7 
software was used for these analyses. A value of p < 0.05 was considered to denote statistical 
significance. 
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CHAPTER 3. RESULTS & DISCUSSION 
 
3.1 Method Development: Selecting an Optimal Solvent 
Varying concentrations of DMSO and ethanol were tested from 0.01% to 0.1 % (v/v) in cell culture 
medium to assess which solvent combination produced approximately or closest to 100% cell 
viability. This was done to ensure little to no interference in the results when assessing compounds. 
These experiments were performed in triplicate for all three cell lines.  
3.1.1 Identifying Optimal Solvent for Use in Future Experiments 
Initially, the cytotoxic effects between DMSO and ethanol were compared to each other to 
determine the optimal solvent. The results show that ethanol produced a higher cell viability across 
all three cancer cell lines from 0.01 to 0.1% (v/v) compared to DMSO. With the exception of 
HeLa, ethanol consistently decreased cell viability in A549 and HCT 116 cells, moreso as the 
concentration of ethanol increased (Figure 1a; 1c). The significant decrease in cell viability 
induced by DMSO correlated with the activity found in the literature as it was reported that higher 
concentrations of DMSO, such as 5% DMSO reduces cell viability by more than 50% (Wang, 
2012).  
 
Figure 1. Cytotoxic effects of DMSO versus ethanol (EtOH) on mammalian cancer cells after 3 
days of treatment as determined by MTT assay. A) A549; B) HeLa; C) HCT 116. Note: Letters 
denote significance of p < 0.05 from a = control, b = 0.01% DMSO, c = 0.01% EtOH, d = 
0.02% EtOH, e = 0.03% EtOH, f = 0.04% EtOH, g = 0.05% EtOH. 
3.1.2 Optimization of Percentage Concentration of Solvent 
As the optimal solvent was identified, a wider concentration range of ethanol concentrations was 
tested from 0.005% to 0.1% (v/v) to determine the optimal solvent concentration. Based on the 
results from all three cancer cell lines, it was found that the concentration ranges from 0.005% to 
0.015% (v/v) ethanol decreased cell viability by only 25%, whereas higher concentrations 
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decreased viability by as much as 75% (Figure 2). From this finding, 0.01% (v/v) ethanol proved 
to be an optimal solvent and was used in the following experiments and preparation of paclitaxel 
and Taxus extracts.  
 
Figure 2. Cytotoxicity effects of varying percent concentrations (v/v) of EtOH on mammalian 
cancer cells after 3 days of treatment. A) A549; B) HeLa; C) HCT 116. Note: Letters denote 
significance of p < 0.05 from a = control, b = 0.005%, c = 0.01%, d = 0.015% (A549 & HCT 
116) or 0.01% (HeLa). 
3.2 Methods Development: Screening of Known Paclitaxel 
Concentrations 
Different concentrations of paclitaxel ranging from 5 µM to 500 µM were tested against HeLa, 
A549, and HCT 116 to determine the extent to which paclitaxel reduced cell viability. Three trials 
of the experiments were performed in triplicate for all three cell lines.  
3.2.1 Paclitaxel Effects on HeLa 
Figure 3 illustrates the three different trials for HeLa, cervical cancer cell line. Each paclitaxel 
concentration from 0 µM to 500 µM reduced cell viability in all trials and were found to be 
statistically significant from the healthy, untreated cells. In comparison to the control, HeLa cells 
generally were found to be 10-40% viable based on the overall paclitaxel concentrations. These 
results indicate that paclitaxel had a cytotoxic effect to over 50% of the cells. Although the cell 
viabilities between the trials differed, there was no statistical significance amongst the paclitaxel 
concentrations within each trial. Furthermore, trial 1 (Figure 3a) showed the least reduction in cell 
viability in comparison to trials 2 and 3 (Figures 3b and c), which showed the greatest reduction 
in cell viability.  
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Figure 3. Cytotoxicity of paclitaxel concentrations from 5 µM to 500 µM against HeLa cells 
after three days of treatment with three separate experimental trials. A) Trial 1; B) Trial 2; C) 
Trial 3. Note: Letters denote significance of p < 0.05 from a = control.  
3.2.2 Paclitaxel Effects on A549 
Figures 4 shows the three different trials for A549, lung cancer cell line. All paclitaxel 
concentrations were found to reduce cell viability and were statistically significant from the 
healthy, untreated cells. As observed in trials 1 and 2 (Figures 4a; 4b), small concentrations of 
paclitaxel (5-10 µM) reduced the overall cell viability compared to high concentrations of 100 and 
500 µM paclitaxel. The paclitaxel concentrations were not statistically significant amongst each 
other in all trials. Additionally, there was no clear correlation between decreased cell viability and 
increasing paclitaxel concentration. However, 500 µM paclitaxel, the highest concentration of 
paclitaxel tested, was consistently the least effective in reducing cell viability in all three trials.  
 
Figure 4. Cytotoxicity of paclitaxel concentrations from 5 µM to 500 µM against A549 cells 
after three days of treatment with three separate experimental trials. A) Trial 1; B) Trial 2; C) 
Trial 3. Note: Letters denote significance of p < 0.05 from a = control.  
3.2.3 Paclitaxel Effects on HCT 116 
Figures 5 shows the three different trials for HCT 116, colon cancer cell line. All paclitaxel 
concentrations were found to reduce cell viability and were statistically significant from the 
healthy, untreated cells; in-depth statistical analyses can be found in Appendix C. Trials 2 and 3 
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(Figure 5b; 5c) show additional statistical significance amongst various paclitaxel concentrations 
in reducing cell viability. For instance, in trial 2 (Figure 5b) paclitaxel at 500 µM is statistically 
significant from the control, 5 µM, and 10 µM. For all three trials, paclitaxel at 100 µM 
consistently had the greatest effect in reducing cell viability. Additionally, there was a clear 
response trend against various concentrations of paclitaxel. Between 5 - 100 µM, the cell viability 
steadily decreases with 100 µM producing the least number of viable cells. However, at 500 µM 
the cells respond positively to the paclitaxel and produce comparatively equal number of viable 
cells as 5-10 µM. 
 
Figure 5. Cytotoxicity of paclitaxel concentrations from 5 µM to 500 µM against HCT 116 
cells after three days of treatment with three separate experimental trials. A) Trial 1; B) Trial 
2; C) Trial 3. Note: Letters denote significance of p < 0.05 from a = control, b = 5 µM, c = 10 
µM.  
3.2.3 Comparison of Paclitaxel Effects from Three Cell Lines 
Although each paclitaxel concentrations induced death in HeLa cells (Figure 6), 100 µM paclitaxel 
showed the most potent effect in decreasing cell viability. 10 µM paclitaxel, in comparison, 
produced the least effect in HeLa cell viability and also had a higher variance compared to other 
paclitaxel concentrations. In the case of A549 (Figure 6a), paclitaxel at 50 µM was found to have 
the most effect in decreasing cell viability while 500 µM paclitaxel had the least reductive effect. 
These results corresponded with the literature as it was reported that higher concentrations of 
paclitaxel have a less potent effect on A549 due to an increased resistance from the higher exposure 
to paclitaxel12. In comparison, paclitaxel at 100 µM was found to have the greatest effect in 
decreasing the overall cell viability of HCT 116 (Figure 6c).  
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Figure 6. Comparison of cytotoxicity effects of paclitaxel concentrations from 5 µM to 500 
µM from all three cancer cell lines after three days of treatment with results average from 
separate experimental trials. A) A549; B) HeLa; C) HCT 116. Note: Letters denote significance 
of p < 0.05 from a = control, b = 5 µM, c = 10 µM.  
Overall, paclitaxel was found to significantly reduce viability in all three cell lines. Although the 
concentrations tested during these experiments were higher than used in literature, it is important 
to note that paclitaxel, even at lower doses (< 10 nM) has been found to cause mitotic arrest and 
induce apoptosis in HeLa and HCT 116 cancer cell lines29,30. In the case of A549, low 
concentrations of paclitaxel were found to cause abnormal division of cells and prolong the mitotic 
stage, thereby leading to the post-mitotic arrest of the cells12. An increase in paclitaxel 
concentration, however, inhibits the pathway that causes a prolonged mitotic stage, leading to a 
mitotic slippage and a greater chance of cells surviving12. For the case of method development, it 
was not necessary to test comparatively low concentrations of paclitaxel we devised standard dose-
responses that can serve as a baseline for the Taxus extracts.  
3.3 Method Validation: Testing Taxus Cell Cultures 
Extracts from Taxus cell lines: 48-82A-2, 48-82A-3, 48-82A-4, 48-82A-32, and 1101-62A-5, were 
obtained based on the elicitation and extraction procedure described in Chapter 2. 48-82A-2, 48-
82A-3, 48-82A-4, and 48-82A-32 are from Taxus chinesis, commonly known as Chinese yew 
(Harvard Arboretum). Plant cell line, 1101-62A-5, is a hybrid of Taxus baccata and Taxus 
cuspidate (Harvard Arboretum). Each plant cell line produced two extracts elicited with either 
MeJa, which was expected to induce specialized metabolite synthesis, or ethanol, which was 
expected to produce little to no paclitaxel (or general specialized metabolites) in the cells. Ten 
plant extracts were tested against HeLa, A549, and HCT 116 to validate the anticancer properties 
of Taxus cultures and verify the effectiveness of the high throughput screening system on plant 
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cell culture extracts. Three trials of the experiments were performed in triplicate for all three cell 
lines.  
3.3.1 Taxus Effects on HeLa 
The addition of all plant extracts found to decrease the cell viability for all three trials (Figure 7). 
Each extract tested was found to be statistically significant with each other at p < 0.05. In-depth 
statistical analyses can be found in Appendix D. For each trial, 48-82A-2 –MeJa had a greater 
effect in reducing cell viability in comparison to its +MeJa counterpart. With regards to 48-82A-
3 and 48-82A-32, +MeJa produced cell viabilities below 20% and was significantly less than –
MeJa. For some cell lines, there were no consistent responses between the MeJA-elicited and 
mock-elicited extracts from all three trials. For instance, 48-82A-4 +MeJa in trial 1 produced a 
comparatively lower cell viability than –MeJa, however, for trials 2 and 3, the behaviors were 
switched. This was also be observed in 1101-62A-5.  
 
Figure 7. Viability of Taxus cell extracts both methyl jasmonate elicited and ethanol (mock) 
elicited against HeLa cells after three days of treatment with three separate experimental trials. 
A) Trial 1; B) Trial 2; C) Trial 3. Note: Letters denote significance of p < 0.05 from a = 
control, b = 48-82A-2 (+MeJa), c = 48-82A-3 (-MeJa), d = 48-82A-3 (+MeJa), e = 48-82A-4 (-
MeJa), f = 48-82A-32 (-MeJa), g = 1101-62A-5 (+MeJa), h = 1101-62A-5 (-MeJa), i = 48-
82A-2 (-MeJa). 
3.3.1 Taxus Effects on A549 
The addition of all plant extracts decreased the cell viability of A549 for all three trials. Each 
extract was found to be statistically significant amongst each other at p < 0.05. In-depth statistical 
analyses can be found in Appendix D. Based on Figure 8, each extract generated relatively similar 
responses on A549 for all three trials. Plant cell extracts +MeJa and –MeJa from 48-82A-2 
appeared to produce similar cell viabilities in all three trials. Although in trials 2 and 3 –MeJa had 
comparatively lower cell viabilities, the standard deviations from both trials were large and 
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therefore statistically  the cell viabilities from both types of extracts were similar to each other. 
Plant extracts, 48-82A-3, 48-82A-4 and 1101-62A-5 +MeJa, followed our initial hypothesis as 
+MeJa extracts decreased the cell viability significantly more than –MeJa in all trials, producing 
cell viabilities less than 20% (Figure 8). Extracts from 48-82A-32, however, responded in an 
opposite manner with –MeJa extracts decreasing the viability to approximately 40%, which is 
significantly lower than that of +MeJa.  
 
Figure 8. Viability of Taxus cell extracts both methyl jasmonate elicited and ethanol (mock) 
elicited against A549 cells after three days of treatment with three separate experimental trials. 
A) Trial 1; B) Trial 2; C) Trial 3. Note: Letters denote significance of p < 0.05 from a = 
control, b = 48-82A-2 (+MeJa), c = 48-82A-3 (-MeJa), d = 48-82A-3 (+MeJa), e = 48-82A-4 (-
MeJa), f = 48-82A-32 (-MeJa), g = 1101-62A-5 (+MeJa), h = 1101-62A-5 (-MeJa), i = 48-
82A-2 (-MeJa). 
3.3.1 Taxus Effects on HCT 116 
The addition of all plant extracts decreased the cell viability of HCT 116 for all three trials. Each 
extract was found to be statistically significant amongst each other at p < 0.05; in-depth statistical 
analyses can be found in Appendix D. Based on Figure 9, extracts from 48-82A-2, 48-82A-3, and 
48-82A-4 generated relatively similar responses as HCT 116 in all three trials. The results obtained 
from plant cell extracts, 48-82A-3 and 48-82A-4 +MeJa, reaffirmed our hypothesis as +MeJa 
extracts produced relatively low cell viabilities of less than 30% and were significantly different 
than –MeJa extracts. Extracts from 48-82A-2 produced an opposite effect as –MeJa caused 0 - 
10% cell viability but were still similar to the effects from +MeJa. Although 48-82A-32 and 1101-
62A-5 produced inconsistent results when considering all three trials, two out of the three trials 
demonstrated that –MeJa had a more potent effect on HCT 116 than +MeJa extracts.  
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Figure 9. Viability of Taxus cell extracts both methyl jasmonate elicited and ethanol (mock) 
elicited against HCT 116 cells after three days of treatment with three separate experimental 
trials. A) Trial 1; B) Trial 2; C) Trial 3. Note: Letters denote significance of p < 0.05 from a = 
control, b = 48-82A-2 (+MeJa), c = 48-82A-3 (-MeJa), d = 48-82A-3 (+MeJa), e = 48-82A-4 (-
MeJa), f = 48-82A-32 (-MeJa), g = 1101-62A-5 (+MeJa), h = 1101-62A-5 (-MeJa), i = 48-
82A-2 (-MeJa). 
3.3.1 Comparison of Taxus Effects from Three Cell Lines 
Generally, the addition of plant extracts decreased the viability of all three mammalian cancer cell 
lines. It was found that 48-82A-3 and 1101-62A-5 showed significant differences amongst extracts 
that were MeJa-elicited and mock-elicited, and also had consistent responses for all three 
mammalian cell lines. 1101-62A-5 significantly decreased the cell viability in HCT 116 and A549 
by approximately 80% with +MeJa, whereas 48-82A-3 demonstrated consistent behavior in all 
three mammalian cell lines producing cell viabilities of 20-30% with +MeJa.  
 
Figure 10. Comparison of cytotoxic effects of Taxus cell extracts both methyl jasmonate 
elicited and ethanol (mock) elicited on all three cell lines after three days of treatment with 
averaged results from separate experimental trials. A) A549; B) HeLa; C) HCT 116. Note: 
Letters denote significance of p < 0.05 from a = control, b = 48-82A-2 (+MeJa), c = 48-82A-3 
(-MeJa), d = 48-82A-3 (+MeJa), e = 48-82A-4 (-MeJa), f = 48-82A-32 (-MeJa), g = 1101-62A-
5 (+MeJa), h = 1101-62A-5 (-MeJa), i = 48-82A-2 (-MeJa). 
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CHAPTER 4. CONCLUSIONS 
From method development to validation, we were able to successfully create a high-throughput 
screening system using plant cell cultures to identify and harness secondary metabolites with 
medicinal properties. Based on the screening platform, we determined 0.01% (v/v) ethanol in 
medium had the least effect in affecting mammalian cell viability. Additionally, by testing known 
concentrations of paclitaxel on the three different cancer lines, we were able to elucidate a general 
dose-response which enabled the estimation of the concentrations of plant cells extracts to add by 
comparing their cytotoxic effects. And discuss how you tested plant extracts and how some of the 
lines had lower viability in the MeJA+ cells. Furthermore, we determined that both MeJa-elicited 
and EtOH-elicited plant cell extracts generally lowered mammalian cancer cell viability with 
MeJa-elicited cells as the more potent of the two, which indicates the possible presence of other 
compounds in the extracts in addition to paclitaxel.  
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CHAPTER 5. FUTURE DIRECTIONS 
To further improve upon the high throughput system developed for this project, we would like to 
expand upon three main areas. As this project optimized the solvent in use, future work can focus 
on the optimization of the screening platform. This can be done by utilizing hydrogels to develop 
three-dimensional (3D) cancer cell cultures of each mammalian cancer line as it mimics the in vivo 
conditions of the cell, thereby allowing for more sensitivity when treated with various plant 
extracts. Additionally, to further validate the effectiveness of the high throughput system in 
detecting the effects of anticancer compounds of plant extracts, we recommend testing plant 
extracts with no known anticancer properties reported in literature to act as a control.  
 
Another area of future work can be performed to further analyze the compounds present in the 
tested Taxus extracts. More specifically, the concentration of paclitaxel present from the five Taxus 
cell lines can be quantified using UPLC analysis. Additionally, as certain cell cultures elicited with 
ethanol produced a lower cell viability in mammalian cancer cells, such as HeLa, we recommend 
performing LC-MS analysis to determine the compounds present to assess any synergistic effects 
responsible for decreasing the cell viability.  
 
Finally, we recommend applying the high throughput system with various plant cell cultures that 
have reported anticancer or medicinal properties in the literature. This can be obtained from the 
collaboration with University of Massachusetts Savinov Lab and the Plant Cell Culture Library. 
The cells can the elicited with both yeast and MeJa to discover novel metabolites, which can later 
be applied to new natural product drug development platform developed here. The co-culture of 
these elicitors, such as endophytic fungi and yeast, would promote synergistic relationship which 
can increase the production of the specialized metabolites. The criteria that was used to which 
plant cell cultures were to be tested was based on mainly their anticancer property, high growth 
activity, and availability for use from the PCCL. The list of plant cell cultures chosen and 
elicitation/extraction methods can be found in Appendix I. 
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APPENDICES 
Appendix A. Solvent Optimization P-charts 
Table 1. Statistical analysis of experiments comparing cytotoxic effects of DMSO and EtOH in 
HeLa cells. Note: D = DMSO; E = EtOH; ns = not significant. 
 
  
 Control 0.01% D 
0.02% 
D 
0.03% 
D 
0.04% 
D 
0.05% 
D 
0.1% 
D 
0.01% 
E 
0.02% 
E 
0.03% 
E 
0.04% 
E 
0.05% 
E 
0.1% 
E 
Control NS             
0.01% 
D  NS            
0.02% 
D   NS           
0.03% 
D    NS      ***    
0.04% 
D     NS     ***    
0.05% 
D      NS    ***    
0.1% D       NS   ***    
0.01% 
E        NS  *    
0.02% 
E         NS *    
0.03% 
E    *** *** *** *** * * NS *** *** *** 
0.04% 
E          *** NS   
0.05% 
E          ***  NS  
0.1% E          ***   NS 
  26 
Table 2.  Statistical analysis of experiments comparing cytotoxic effects of DMSO and EtOH in 
A549 cells. Note: D = DMSO; E = EtOH; ns = not significant 
 
  
 Control 0.01% D 
0.02% 
D 
0.03% 
D 
0.04% 
D 
0.05% 
D 
0.1% 
D 
0.01% 
E 
0.02% 
E 
0.03% 
E 
0.04% 
E 
0.05% 
E 
0.1% 
E 
Control NS **** **** **** **** **** **** * **** **** **** **** **** 
0.01% 
D **** NS ** ** ** ** ** ***   * * ** 
0.02% 
D **** ** NS     **** **** ****    
0.03% 
D **** **  NS    ****      
0.04% 
D **** **   NS   **** **** ****    
0.05% 
D **** **    NS  **** **** ****    
0.1% D **** **     NS **** **** ****    
0.01% 
E * *** **** **** **** **** **** NS *  **** **** **** 
0.02% 
E ****  **** **** **** **** **** * NS  **** **** **** 
0.03% 
E ****  ****  **** **** ****   NS **** **** **** 
0.04% 
E **** *      **** **** **** NS   
0.05% 
E **** *      **** **** ****  NS  
0.1% E **** **      **** **** ****   NS 
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Table 3.  Statistical analysis of experiments comparing cytotoxic effects of DMSO and EtOH in 
HCT 116 cells. Note: D = DMSO; E = EtOH; ns = not significant 
 
  
 Control 0.01% D 
0.02% 
D 
0.03% 
D 
0.04% 
D 
0.05% 
D 
0.1% 
D 
0.01% 
E 
0.02% 
E 
0.03% 
E 
0.04% 
E 
0.05% 
E 
0.1% 
E 
Control NS **** **** **** **** **** **** **** **** **** **** **** **** 
0.01% 
D **** NS *** **** *** ****        
0.02% 
D **** *** NS     **** *     
0.03% 
D **** ****  NS    **** **  *   
0.04% 
D **** ***   NS   **** **     
0.05% 
D **** ****    NS  **** ** * * *  
0.1% D ****      NS       
0.01% 
E ****  **** **** **** ****  NS ** **** **** **** **** 
0.02% 
E ****  * ** ** **  ** NS     
0.03% 
E ****     *  ****  NS    
0.04% 
E ****   *  *  ****   NS   
0.05% 
E ****     *  ****    NS  
0.1% E ****       ****     NS 
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Appendix B. Solvent Concentration Optimization P-charts 
Table 4.  Statistical analysis of experiments determining optimal EtOH concentration in HeLa 
cells.  
 
Table 5.  Statistical analysis of experiments determining optimal EtOH concentration in A549 
cells.  
 
 
 
  
 Control 0.005% 0.01%  0.015%  0.02%  0.025%  0.03%  0.035%  0.04%  0.045%  0.05%  0.1%  
Control NS ** *** ** **** **** **** **** **** **** **** **** 
0.005%  ** NS      * * *   
0.01%  ***  NS      *    
0.015%  **   NS    * * *   
0.02%  ****    NS        
0.025%  ****     NS       
0.3%  ****      NS      
0.035%  ****       NS     
0.04%  **** *  *     NS    
0.045%  **** * * *      NS   
0.05%  **** *  *       NS  
0.1%  ****           NS 
 Control 0.005% 0.01%  0.015%  0.02%  0.025%  0.03%  0.035%  0.04%  0.045%  0.05%  0.1%  
Control NS    * * *** *** *** *** *** **** 
0.005%   NS     ** ** ** ** ** *** 
0.01%    NS         * 
0.015%     NS   ** ** *** *** ** *** 
0.02%  *    NS        
0.025%  *     NS       
0.3%  *** **  **   NS      
0.035%  *** **  **    NS     
0.04%  *** **  ***     NS    
0.045%  *** **  ***      NS   
0.05%  *** **  **       NS  
0.1%  **** *** * ***        NS 
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Table 6.  Statistical analysis of experiments determining optimal EtOH concentration in HCT116 
cells.  
 
  
 Control 0.005% 0.01%  0.015%  0.02%  0.025%  0.03%  0.035%  0.04%  0.045%  0.05%  0.1%  
Control NS  * ** ** **** **** **** **** **** **** **** 
0.005%   NS * * * **** *** **** **** **** **** **** 
0.01%  * * NS      *   *** 
0.015%  ** *  NS        ** 
0.02%  ** *   NS       ** 
0.025%  **** ****    NS       
0.3%  **** ***     NS      
0.035%  **** ****      NS     
0.04%  **** **** *      NS    
0.045%  **** ****        NS   
0.05%  **** ****         NS  
0.1%  **** **** *** ** **       NS 
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Appendix C. Paclitaxel Experiments P-charts 
C.i A549 cells 
Table 7.  Statistical analysis of A549 cells viability when treated with paclitaxel from a 
concentration range of 5 µM to 500 µM under three trials.  
 
 
 
 
 
  
 
Table 8.  Statistical analysis of A549 cells viability when treated with paclitaxel from a 
concentration range of 5 µM to 500 µM averaged from three trials.  
 
 
 
 
 
 
C.ii HeLa cells 
Table 9.  Statistical analysis of HeLa cells viability when treated with paclitaxel from a 
concentration range of 5 µM to 500 µM under three trials.  
 
 
 
 
 
 
 
Table 10.  Statistical analysis of HeLa cells viability when treated with paclitaxel from a 
concentration range of 5 µM to 500 µM averaged from three trials.  
 
 
  
 Trial 1 Trial 2 Trial 3 
Control **** **** **** 
5 µM **** **** **** 
10 µM **** **** **** 
50 µM **** **** **** 
100 µM **** **** **** 
500 µM **** **** **** 
 Control 5 µM 10 µM 50 µM 100 µM 500 µM 
Control NS **** **** **** **** **** 
5 µM **** NS     
10 µM ****  NS    
50 µM ****   NS   
100 µM ****    NS  
500 µM ****     NS 
 Trial 1 Trial 2 Trial 3 
Control **** **** **** 
5 µM **** **** **** 
10 µM **** **** **** 
50 µM **** **** **** 
100 µM **** **** **** 
500 µM **** **** **** 
 Control 5 µM 10 µM 50 µM 100 µM 500 µM 
Control NS **** **** **** **** **** 
5 µM **** NS     
10 µM ****  NS    
50 µM ****   NS   
100 µM ****    NS  
500 µM ****     NS 
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C.iii HeLa cells 
Table 11.  Statistical analysis of HCT116 cells viability when treated with paclitaxel from a 
concentration range of 5 µM to 500 µM for trial 1.  
 
 
 
 
 
 
 
Table 12.  Statistical analysis of HCT116 cells viability when treated with paclitaxel from a 
concentration range of 5 µM to 500 µM for trial 2. Note: NS = not significant.  
 
 
 
 
 
 
 
 
Table 13.  Statistical analysis of HCT116 cells viability when treated with paclitaxel from a 
concentration range of 5 µM to 500 µM for trial 3. Note: NS = not significant.  
 
 
 
 
 
 
 
Table 14.  Statistical analysis of HCT116 cells viability when treated with paclitaxel from a 
concentration range of 5 µM to 500 µM averaged from three trials. Note: NS = not significant. 
  
 Trial 1 
Control **** 
5 µM **** 
10 µM **** 
50 µM **** 
100 µM **** 
500 µM **** 
 Control 5 µM 10 µM 50 µM 100 µM 500 µM 
Control NS **** **** **** **** **** 
5 µM **** NS  **** **** **** 
10 µM ****  NS *** **** **** 
50 µM **** **** *** NS   
100 µM **** **** ****  NS  
500 µM **** **** ****   NS 
 Control 5 µM 10 µM 50 µM 100 µM 500 µM 
Control NS **** **** **** **** **** 
5 µM **** NS   *  
10 µM ****  NS    
50 µM ****   NS   
100 µM **** *   NS  
500 µM ****     NS 
 Control 5 µM 10 µM 50 µM 100 µM 500 µM 
Control NS **** **** **** **** **** 
5 µM **** NS  **** ****  
10 µM ****  NS ** ***  
50 µM **** **** ** NS   
100 µM **** **** ***  NS * 
500 µM ****    * NS 
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Appendix D. Taxus Experiments P-charts 
D.i A549 cells 
Table 15.  Statistical analysis of A549 cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa for trial 1. Note: NS = not significant, + denotes +MeJa, - denotes –MeJa, 
2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
 
Table 16.  Statistical analysis of A549 cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa for trial 2. Note: NS = not significant, + denotes +MeJa, - denotes –MeJa, 
2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
 
  
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS **** **** **** **** ****  **** **** **** **** 
2+ **** NS     **     
2- ****  NS    **     
3+ ****   NS   ***     
3- ****    NS  **     
4+ ****     NS **     
4-  ** ** *** ** ** NS * ** ** ** 
32+ ****      * NS    
32- ****      **  NS   
5+ ****      **   NS  
5- ****      **    NS 
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS   *        
2+  NS   *      ** 
2-   NS  *     ** ** 
3+ *   NS       ** 
3-  * *  NS * *  * **  
4+     * NS     ** 
4-     *  NS    * 
32+        NS   * 
32-     *    NS  * 
5+   **  **     NS ** 
5-  ** ** **  ** * * * ** NS 
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Table 17.  Statistical analysis of A549 cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa for trial 3. Note: NS = not significant, + denotes +MeJa, - denotes –MeJa, 
2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
 
Table 18.  Statistical analysis of A549 cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa averaged from 3 trials. Note: NS = not significant, + denotes +MeJa, - 
denotes –MeJa, 2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
 
  
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS ** ** ***  *   * ***  
2+ ** NS   ****      ** 
2- **  NS  ****      ** 
3+ ***   NS ****  * *   *** 
3-  **** **** **** NS ***   *** ****  
4+ *    *** NS      
4-    *   NS     
32+    *    NS    
32- *    ***    NS   
5+ ***    ****  * *  NS *** 
5-  ** ** ***      *** NS 
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS **** **** **  *** ** * *** ****  
2+ **** NS   ****      **** 
2- ****  NS  ****      **** 
3+ **  **** NS ****      * 
3-  **** **** **** NS **** **** **** **** **** **** 
4+ ***    **** NS     *** 
4- **    ****  NS    * 
32+ *    ****   NS    
32- ***    ****    NS  ** 
5+ ****    ****     NS *** 
5-  **** **** * **** *** *  ** *** NS 
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D.ii HeLa cells 
Table 19.  Statistical analysis of HeLa cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa for trial 1. Note: NS = not significant, + denotes +MeJa, - denotes –MeJa, 
2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
Table 20.  Statistical analysis of HeLa cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa for trial 2. Note: NS = not significant, + denotes +MeJa, - denotes –MeJa, 
2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
 
  
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS  * *  **  *  ** * 
2+  NS * *  **  *  ** * 
2- * * NS  *       
3+ * *  NS *       
3-   * * NS **  *  ** ** 
4+ ** **   ** NS      
4-       NS     
32+ * *   *   NS    
32-         NS   
5+ ** **   **     NS  
5- * *   **      NS 
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS           
2+  NS          
2-   NS      *   
3+    NS     *   
3-     NS       
4+      NS   *   
4-       NS  **   
32+        NS *   
32-   * *  * ** * NS * * 
5+         * NS  
5-         *  NS 
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Table 21.  Statistical analysis of HeLa cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa for trial 3. Note: NS = not significant, + denotes +MeJa, - denotes –MeJa, 
2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
 
Table 22.  Statistical analysis of HeLa cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa averaged from 3 trials. Note: NS = not significant, + denotes +MeJa, - 
denotes –MeJa, 2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
 
 
  
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS      * *    
2+  NS          
2-   NS         
3+    NS        
3-     NS  * *    
4+      NS      
4- *    *  NS     
32+ *    *   NS    
32-         NS   
5+          NS  
5-           NS 
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS ** *** ****  *** *** ****  **** **** 
2+ ** NS          
2- ***  NS  **       
3+ ****   NS **       
3-   ** ** NS * * **  ** ** 
4+ ***    * NS      
4- ***    *  NS     
32+ ****    **   NS    
32-         NS   
5+ ****    **     NS  
5- ****    **      NS 
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D.iii HCT116 cells 
Table 23.  Statistical analysis of HCT116 cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa for trial 1. Note: NS = not significant, + denotes +MeJa, - denotes –MeJa, 
2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
 
Table 24.  Statistical analysis of HCT116 cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa for trial 2. Note: NS = not significant, + denotes +MeJa, - denotes –MeJa, 
2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
 
  
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS **** **** **** * **** **** **** **** **** **** 
2+ **** NS   ****       
2- ****  NS  ****       
3+ ****   NS ****       
3- * **** **** **** NS **** **** **** **** **** **** 
4+ ****    **** NS      
4- ****    ****  NS     
32+ ****    ****   NS    
32- ****    ****    NS   
5+ ****    ****     NS  
5- ****    ****      NS 
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS **** **** **** * **** **** **** **** * **** 
2+ **** NS   ****     **** ** 
2- ****  NS * ****     **** *** 
3+ ****  * NS ****     *  
3- * **** **** **** NS **** **** **** **** **** **** 
4+ ****    **** NS    *** * 
4- ****    ****  NS   **  
32+ ****    ****   NS  **  
32- ****    ****    NS ***  
5+ * **** **** * **** *** ** ** *** NS  
5- **** ** ***  **** *     NS 
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Table 25.  Statistical analysis of HCT116 cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa for trial 3. Note: NS = not significant, + denotes +MeJa, - denotes –MeJa, 
2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
 
Table 26.  Statistical analysis of HCT116 cells viability when treated with Taxus extracts elicited 
with +MeJa or -MeJa averaged from 3 trials. Note: NS = not significant, + denotes +MeJa, - 
denotes –MeJa, 2 = 48-82A-2, 3 = 48-82A-3, 4 = 48-82A-4, 32 = 48-82A-32, 5 = 1101-62A-5.  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS **** **** **** *** **** **** **** **** ** **** 
2+ **** NS   ****  *   ****  
2- ****  NS  ****  *   ****  
3+ ****   NS ****     ****  
3- *** **** **** **** NS **** **** **** **** **** **** 
4+ ****    **** NS *   ****  
4- **** * *  **** * NS   *  
32+ ****    ****   NS  ****  
32- ****    ****    NS **  
5+ ** **** **** **** **** **** * **** ** NS **** 
5- ****    ****     **** NS 
 Control 2+ 2- 3+ 3- 4+ 4- 32+ 32- 5+ 5- 
Control NS **** **** **** **** **** **** **** **** **** **** 
2+ **** NS   ****  **   **** *** 
2- ****  NS  ****  **   **** **** 
3+ ****   NS ****     ****  
3- **** **** **** **** NS **** **** **** **** **** **** 
4+ ****    **** NS    **** ** 
4- **** ** **  ****  NS   ***  
32+ ****    ****   NS  **** * 
32- ****    ****    NS ****  
5+ **** **** **** **** **** **** *** **** **** NS ** 
5- **** *** ****  **** **  *  ** NS 
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Appendix E. Solvent Optimization Raw Data 
Table 27.  Raw data of A549 cells viability when treated with DMSO and EtOH from a 
concentration range of 0.01% to 0.1% (v/v) under three trials. 
 
 
 
 
 
 
 
 
Table 28.  Raw data of HeLa cells viability when treated with DMSO and EtOH from a 
concentration range of 0.01% to 0.1% (v/v) under three trials. 
 
 
 
 
 
 
 
 
  
 Trial 1 Trial 2 Trial 3 
Control 84.48 108.16 107.36 
0.01% DMSO 31.12 39.26 32.72 
0.02% DMSO 5.52 2.72 3.12 
0.03% DMSO 3.36 2.16 1.04 
0.04% DMSO 1.52 1.36 0.56 
0.05% DMSO 1.84 0.8 1.2 
0.1% DMSO 1.6 1.28 0.88 
0.01% EtOH 71.76 58.88 90.32 
0.02% EtOH 60 35.44 53.28 
0.03% EtOH 44.72 57.94 50.56 
0.04% EtOH 3.28 13.68 12.56 
0.05% EtOH 8.08 4.8 8.72 
0.1% EtOH 1.36 2.8 1.04 
 Trial 1 Trial 2 Trial 3 
Control 82.11 91.06 126.83 
0.01% DMSO 100.81 78.46 147.15 
0.02% DMSO 42.28 43.50 40.65 
0.03% DMSO 15.85 17.48 17.073 
0.04% DMSO 16.26 16.67 17.073 
0.05% DMSO 15.45 18.09 14.63 
0.1% DMSO 15.04 16.26 16.67 
0.01% EtOH 51.22 65.85 97.15 
0.02% EtOH 161.38 97.97 74.39 
0.03% EtOH 192.28 84.96 322.36 
0.04% EtOH 36.59 28.46 16.26 
0.05% EtOH 23.98 20.33 36.99 
0.1% EtOH 23.58 16.67 25.20 
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Table 29.  Raw data of HCT116 cells viability when treated with DMSO and EtOH from a 
concentration range of 0.01% to 0.1% (v/v) under three trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Trial 1 Trial 2 Trial 3 
Control 98.01 91.07 110.86 
0.01% DMSO 55.43 57.26 50.71 
0.02% DMSO 9.89 18.12 13.09 
0.03% DMSO 3.35 1.83 1.68 
0.04% DMSO 0 0.30 0 
0.05% DMSO 0 0.15 0 
0.1% DMSO 0 0 0 
0.01% EtOH 72.94 57.26 67.31 
0.02% EtOH 46.14 34.42 35.63 
0.03% EtOH 28.02 29.69 37.16 
0.04% EtOH 30.61 27.56 31.07 
0.05% EtOH 30.61 27.56 31.07 
0.1% EtOH 42.33 38.22 28.32 
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Appendix F. Solvent Concentration Optimization Raw Data 
Table 30.  Raw data of A549 cells viability when treated with EtOH from a concentration range 
of 0.005% to 0.1% (v/v) under three trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 31.  Raw data of HeLa cells viability when treated with EtOH from a concentration range 
of 0.005% to 0.1% (v/v) under three trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Trial 1 Trial 2 Trial 3 
Control 44.89 138.29 116.81 
0.005% 101.06 79.79 76.17 
0.01% 42.77 61.49 67.45 
0.015% 92.55 82.55 98.72 
0.02% 64.68 55.11 22.13 
0.025% 27.02 19.78 55.11 
0.03% 9.79 18.09 25.96 
0.035% 26.59 11.06 14.68 
0.04% 9.57 14.26 15.74 
0.045% 12.34 7.87 19.15 
0.05% 23.19 19.79 13.40 
0.1% 2.77 3.62 3.83 
 Trial 1 Trial 2 Trial 3 
Control 132.28 93.04 74.68 
0.005% 53.79 46.83 41.77 
0.01% 41.77 36.08 51.89 
0.015% 77.85 36.08 27.22 
0.02% 17.72 29.11 22.15 
0.025% 12.66 13.92 13.29 
0.03% 26.58 11.39 22.15 
0.035% 6.96 11.39 7.59 
0.04% 7.59 4.43 3.79 
0.045% 5.06 10.76 6.96 
0.05% 8.86 17.72 10.13 
0.1% 17.09 27.22 10.76 
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Table 32.  Raw data of HCT116 cells viability when treated with EtOH from a concentration 
range of 0.005% to 0.1% (v/v) under three trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Trial 1 Trial 2 Trial 3 
Control 107.09 94.47 98.44 
0.005% 102.41 118.32 70.85 
0.01% 54.95 56.12 59.86 
0.015% 38.11 36.01 87.22 
0.02% 52.61 63.83 43.02 
0.025% 32.74 21.75 34.37 
0.03% 28.99 39.28 32.50 
0.035% 40.92 16.61 23.85 
0.04% 22.21 18.23 18.94 
0.045% 14.96 24.55 27.83 
0.05% 26.89 26.42 17.77 
0.1% 2.81 1.40 0.93 
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Appendix G. Paclitaxel Experiments P-charts 
Table 33.  Raw data of A549 cells viability when treated with paclitaxel from a concentration 
range of 5 µM to 500 µM averaged from three experimental trials.  
 
 
 
 
 
  
 
Table 34.  Raw data of HeLa cells viability when treated with paclitaxel from a concentration 
range of 5 µM to 500 µM averaged from three experimental trials.  
 
 
 
 
 
  
 
Table 35.  Raw data of HCT116 cells viability when treated with paclitaxel from a concentration 
range of 5 µM to 500 µM averaged from three experimental trials.  
 
 
 
 
 
  
  
 Trial 1 Trial 2 Trial 3 
Control 100 100 100 
5 µM 10.03 9.49 18.39 
10 µM 7.55 15.19 10.96 
50 µM 25.89 17.59 7.19 
100 µM 8.93 6.39 11.68 
500 µM 27.79 30.66 19.18 
 Trial 1 Trial 2 Trial 3 
Control 100 100 100 
5 µM 30.56 17.79 17.15 
10 µM 33.33 20.06 21.68 
50 µM 27.78 20.06 19.19 
100 µM 33.33 17.79 14.49 
500 µM 26.67 20.39 18.12 
 Trial 1 Trial 2 Trial 3 
Control 100 100 100 
5 µM 27.18 32.99 24.78 
10 µM 25.90 22.99 15.57 
50 µM 18.07 5.03 9.02 
100 µM 12.65 4.91 4.50 
500 µM 20.09 5.94 15.78 
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Appendix H. Taxus Experiments Raw Data 
Table 36.  Raw data of A549 cells viability when treated with Taxus extracts elicited with +MeJa 
or –MeJa averaged from three experimental trials.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 37.  Raw data of HeLa cells viability when treated with Taxus extracts elicited with +MeJa 
or –MeJa averaged from three experimental trials.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Trial 1 Trial 2 Trial 3 
Control 100 100 100 
2+ 7.81 7.69 19.67 
2- 9.05 15.38 12.50 
3+ 1.96 5.13 3.28 
3- 16.05 76.32 100 
4+ 7.19 21.05 37.70 
4- 81.69 35.90 70.49 
32+ 21.24 48.72 50.82 
32- 12.09 25 107.05 
5+ 12.96 12.82 6.56 
5- 11.11 89.99 70.49 
 Trial 1 Trial 2 Trial 3 
Control 100 100 100 
2+ 35.85 30.19 38.10 
2- 20.75 16.98 18.87 
3+ 16.98 9.52 16.98 
3- 111.90 121.42 73.58 
4+ 4.81 20.76 32.08 
4- 73.81 9.52 7.55 
32+ 20.75 16.67 6.73 
32- 45.28 76.19 7.14 
5+ 7.55 7.69 26.19 
5- 14.29 11.32 20.75 
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Table 38.  Raw data of HCT116 cells viability when treated with Taxus extracts elicited with 
+MeJa or –MeJa averaged from three experimental trials.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Trial 1 Trial 2 Trial 3 
Control 100 100 100 
2+ 12 5 11 
2- 15 4 10 
3+ 13 38 17 
3- 100 100 100 
4+ 13 16 6 
4- 27 27 27 
32+ 5 16 7 
32- 7 26 36 
5+ 33 68 66 
5- 42 47 21 
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Appendix H. Mammalian Cell Imaging 
 
 
Figure 11. Representative images of HCT116, A549, and HeLa under various conditions such 
as 5 µM paclitaxel, MeJa-elicited Taxus extracts, and mock-elicited Taxus extracts after 3 days 
of treatment. Images taken with brightfield microscopy. Scale bar = 100 µm. 
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Appendix I. PCCL Plant Cell Extracts 
I.i Excel Spreadsheet of Plant Cell Cultures 
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I.ii Cell Cultures 
These cultures were prepared and elicited by undergraduates, Matthew Tauras and Zain Chaudry, 
under the guidance of Professor Sergey Savinov.  
 
+  1) CP-13934 
2) DA-
00132-
R0 
3) EK-
02128-
R1 
4)EO-
11611 
5) GG-
01114-E1 
6) CP-
13934 
7) DA-
00132-
R0 
8)EK-
02128-
R1  
9) EO-
11611 
10) GG-
01114-E1 -  
+  
11)HL-
00210-
R0 
12) 
IT1943-
R0 
13) MP-
10828 
14) OV-
13911 
15) SA-
02878-G4 
16)HL-
00210-
R0 
17) 
IT1943-
R0 
18) MP-
10828 
19) OV-
13911 
20) SA-
02878-G4 -  
+  21) SP-09233 
22) 
TD944-
R0 
23)VR-
10031-
R1 
24) 
CA3068
-G5 
25) EP-
12317 
26) SP-
09233 
27) 
TD944-
R0 
28)VR-
10031-
R1 
29) 
CA3068
-G5 
30)EP-
12317  -  
+  31) RS-07801 
32) HA-
09891-
R1 
33) PC-
11506-
R1 
34) RO-
00231-
L1 
35) 
HF2244 
36)RS-
07801 
37) HA-
09891-
R1 
38) PC-
11506-
R1 
39)RO-
00231-
L1 
40) 
HF2244 -  
+  41) DS-01138 
42) GD-
13212 
C1 
43) HP-
02360 
44) PV-
13684 
C1 
45)MO74
8-T4-L1 
46)DS-
01138 
47) GD-
13212 
C1 
48) HP-
02360 
49)PV-
13684 
C1  
50) 
MO748-
T4-L1 
-  
+  51) RI-00691 
52) CC-
04646 
53) EM-
10045 
54) DI-
07051 
55) 
HI2192-
G4 
56) RI-
00691 
57) CC-
04646 
58) EM-
10045 
59) DI-
07051 
60)HI219
2-G4 -  
+  61) NS-05192 
62) SA-
02880-
R0 
63) 
SM2989
-R1 
64) 
AH279-
G15 
65) CJ-
11831 
66) NS-
05192 
67) SA-
02880-
R0  
68)SM2
989-R1 
69) 
AH279-
G15 
70) CJ-
11831 -  
+  
71)PV-
12067 
C1 
72) 
CS1952-
R1 
73) RO-
14482-
C2 
74) AL-
01796-
L1 
75) CP-
10715-R1 
76) PV-
12067 
C1 
77)CS19
52-R1 
78) RO-
14482-
C2 
79)AL-
01796-
L1 
80)CP-
10715-R1  -  
 
1 and 6) CP-13934 
2 and 7) DA-00132-R0 
3 and 8) EK-02128-R1 
4 and 9) EO-11611 
5 and 10)GG-01114-E1 
11 and 16) HL-00210-R0 
12 and 17) IT1943-R0 
13 and 18) MP-10828 
14 and 19) OV-13911 
15 and 20) SA-02878-G4 
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21 and 26) SP-09233 
22 and 27) TD944-R0 
23 and 28) VR-10031-R1 
24 and 29) CA3068-G5 
25 and 30) EP-12317 
31 and 36) RS-07801 
32 and 37) HA-09891-R1 
33 and 38) PC-11506-R1 
34 and 39) RO-00231-L1 
35 and 40) HF2244 
41 and 46) DS-01138 
42 and 47) GD-13212 C1 
43 and 48) HP-02360 
44 and 49) PV-13684 C1 
45 and 50) MO748-T4-L1 
51 and 56) RI-00691 
52 and 57) CC-04646 
53 and 58) EM-10045 
54 and 59) DI-07051 
55 and 60) HI2192-G4 
61 and 66) NS-05192 
62 and 67) SA-02880-R0 
63 and 68) SM2989-R1 
64 and 69) AH279-G15 
65 and 70) CJ-11831 
71 and 76) PV-12067 C1 
72 and 77) CS1952-R1 
73 and 78) RO-14482-C2 
74 and 79) AL-01796-L1 
75 and 80) CP-10715-R1\ 
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I.ii Protocols 
Preparing Yeast 
 
Media we will be using for yeast will be TSB. Will ask antifungal team to help us out 
with recipes and general culture preparation. We will do a test run with a yeast culture before 
running the actual experiment to optimize the growth yeast. We want to optimize the yeast to get 
10^6 CFU (colony forming unit). The yeast by itself will be the negative control.  
 Once optimized and ready for the experiment,we will fill every well with yeast overnight 
and dilute with TSB, til we get 10^6 CFU.  
 
 
 
Elicitation with Yeast 
 
 When aliquotes are in the wells, we then start the elicitation experiment. Add yeast @ 
10^6 CFU in TSB. Shake the co-culture overnight @ room temperature. (not over stress, look 
into RPM for liquid suspension experiment  approx 100) Spin down plate using regular 
centrifuge to pellet the cellular debris at the bottom of wells. After this, use multichannel pipette 
to transfer the supernatents to new 96-well plate. We then spin down the plate in evaporative 
centrifuge (@ 30 degrees C for both settings) until yellowing brownish residue remains in the 
plate. If there is still residual water, we will use NaSO4 to soak up. (Not needed if evap 
centrifuge works correctly)We will then add 100µL of 100% ethanol to wells in the new plate 
and proceed to sonicate with ice added to the sonicator for 30 minutes until the residue is 
yellowish-brown in the liquid phase. After sonication, we spin down using regular centrifuge.  
Transfer the liquid to new 96 well plate with conical bottom (this will be the third plate we will 
be using. With the new 3rd plate, we then vacuum centrifuge (or gentle air flow) to evaporate 
volatiles. Once dry, seal with parafilm and put into freezer. 
 
 
 
Elicitation with MeJe 
 
MeJe is used in the well (approximately 1mM per well). We will use autoclaved liquid 
MS media with vitamins and sugar for this experiment to reduce the stress on the plant cells. We 
will add together 1mM MJ in 100mL liquid MS.(add 0.01 mmol of MJ -> 2.24 mg -> 2.18 uL). 
These two will be together before pipetting into 96 well, so we just have to transfer once to plate 
using a multichannel pipette and a reservoir. Incubate with this media overnight in a shaker at 
RT and 100RPM. Pipet liquid at the bottom of the culture to leave just the cells on the plate. 
Wash with MS ¼ strength (25% MS 75% sterile water) .<---- potentially skip if we take a 
sufficient amount of water out.  Add methanol to lyse plant cells and then place on shaker for a 
couple of hours. Sonicate if pigmented cells do not release their pigments. Spin down using 
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regular centrifuge at max rpm and rt . Transfer liquid supernatant to 96 well storage plate with a 
conical bottom. Evaporate to dryness via vacuum centrifuge or gentle air flow. Once dry, seal 
with parafilm and put into freezer.  
 
 
In Lab Procedure- 
Done on 3/24/18 
 
Yeast 
● Took plates out of the shaker 
● Prior to centrifugation 
○ Filled an empty plate with water to balance 
○ Balanced plates with the right amount of water 
○ Put in centrifuge --> Ran at max rpm (4000)for 15 mins 
○ Applied parafilm to plates to prevent bumping out of wells 
● 1st Centrifugation 
○ Spun at 4 degree for 15 mins 
○ Spun again at same conditions for 15 min for a total of 30 mins 
● Supernatant Transfer 
○ Transferred to a new 96 well plate 
● Evap Centrifuge 
○ At 30 degrees for 2 hours initially 
○ Balanced with another empty plate 
○ Ethanol to be added post centrifugation at room temp 
● Ethanol added at 1:39 
● Sonicated for 30 mins 
● Spun in regular centrifuge for 20 mins at 4 degree at 4000 rpm 
● Transferred to new plate 
● Evap centrifuge for 45 mins 
  
MeJe 
● Wash plant cells with MS (25%) and H20 (75%) sterile 
○ Prepped 60 mLs of this media and added to reservoir 
● Cells were washed and the solution in wells was discarded 
● Methanol is added to the wells now to aid in lysing the cells 
● Methanol added and cells were placed on shaker at room temp (started at 11:00 rpm of 
120 for 2 hours) 
● At 1:30, removed from shaker 
● Placed in bath sonicator at 1:39 for 30 minutes 
● Placed in centrifuge with the yeast sample. Spun for 20 mins at 4 degree at 4000 rpm. 
● Transferred to new plate 
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● Evap centrifuge for 45 mins 
  
 
 
